Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06949800 · ClinicalTrials.gov registry record · Phase 2
CASCADE 2002: PROTECT Study, "PRObiotics to TrEat Anal preCancer Trial
A Phase 2 study, sponsored by University of California, San Francisco.
- Not yet
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
NCT06949800 is a Phase 2 study that has not yet begun recruiting, run by University of California, San Francisco. The registered enrollment target is 90 participants.
The verdict
NCT06949800, a Phase 2 study, has not yet begun recruiting, sponsored by University of California, San Francisco.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
Study Summary
This study is focused on treatment of anal high-grade squamous intraepithelial lesions (HSIL) in persons with HIV (PWH), with the ultimate goal of applying the approach toward prevention of anal cancer in this population
Interventions
- DRUG Placebo
- DRUG EXE-346 Probiotic
- PROCEDURE Usual Care High Resolution Anoscopy (HRA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2026-06-01 |
| Est. Completion | 2027-05-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06949800
The ClinicalTrials.gov registry entry for NCT06949800 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT06949800 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06949800 about?
NCT06949800 is a clinical study titled "CASCADE 2002: PROTECT Study, "PRObiotics to TrEat Anal preCancer Trial". This study is focused on treatment of anal high-grade squamous intraepithelial lesions (HSIL) in persons with HIV (PWH), with the ultimate goal of applying the approach toward prevention of anal cancer in this population
What is the current status of trial NCT06949800?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2026-06-01. Estimated completion is 2027-05-31.
What interventions are being tested in trial NCT06949800?
The interventions under investigation include: Placebo (DRUG), EXE-346 Probiotic (DRUG), Usual Care High Resolution Anoscopy (HRA) (PROCEDURE).
Who is sponsoring clinical trial NCT06949800?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.